Top 10 Diversified Bank Stocks To Watch For 2015: Aegerion Pharmaceuticals Inc.(AEGR)
Aegerion Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases. The company focuses on therapeutics to treat severe inherited lipid disorders. Lipids are naturally occurring molecules, such as cholesterol and triglycerides that are transported in the blood. Its lead product, lomitapide has completed pivotal Phase III clinical trial to treat patients with a rare inherited lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The company also plans to develop lomitapide for the treatment of adult patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.Advisors' Opinion:
- [By Keith Speights]
Aegerion Pharmaceuticals (NASDAQ: AEGR ) received FDA approval in late 2012 for Juxtapid in the treatment of HoFH. Soon afterward, the FDA approved another drug targeting HoFH, Kynamro, which was developed by Isis Pharmaceuticals (NASDAQ: ISIS ) and marketed by Sanofi's (NYSE: SNY ) Genzyme unit.
- [By David Williamson]
It looks like the CHMP, Europe's version of the FDA advisory committee, didn't want the month to end without two big positive opinions, giving investors a nice little present heading into the weekend.Celgene's (NASDAQ: CELG ) relapsed and refractory multiple myeloma drug pomalidomide, and Aegerion's (NASDAQ: AEGR ) HoFH drug Juxtapid, are now likely to be approved in the EU.
source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-10-diversified-bank-stocks-to-watch-for-2015.html